期刊文献+

急性脑梗死患者血清基质金属蛋白酶-2、基质金属蛋白酶组织抑制因子-2的变化及其意义 被引量:2

Study on serum MMP- 2 and TIMP-- 2 in acute cerebral infarction patients
原文传递
导出
摘要 目的观察急性脑梗死患者血清基质金属蛋白酶-2(MMP-2)及基质金属蛋白酶组织押制因子-2(TIMP-2)水平的变化,探讨其在急性脑梗死的发病机制中的作用及临床意义。方法采用酶联免疫吸附法对56例急性脑梗死患者(CI组)及49例健康时照组(NC组)进行血清MMP-2、TIMP-2测定。结果CI组血清MMP-2水平在发病后呈先增高后降至NC组水平的趋势,病程〈24h、2~5d、28d分别为(46.29±14.37)μg/L、(62.18±12.32)μg/L、(35.72±8.91)μg/L,其中以2~5d时最高,与CI组病程〈24h、28d、NC组比较有显著性差异(P〈0.05)。CI组血清TIMP-2水平在病程〈24h、2~5d、28d分别为(186.14±27.91)μg/L、(160.62±25.49)μg/L、(189.01±33.17)μg/L,其中以2~5d时最低,与CI组病程〈24h、28d、NC组比较有显著性差异(P〈0.05)。结论急性脑梗死患者存在血清MMP-2、TIMP-2水平异常,提示MMP-2、TIMP-2参入脑梗死病理过程。 Objective To observe the alterations of serum matrix metalloproteinase--2 (MMP-- 2) and tissue metalkoproteinase inhibitor--2 (TIMP--2) in acute cerebral infarction patients, and to explore their rote and clinical significance in the development of this disease. Methods The levels of serum MMP--2 and TIMP--2 were determined in 56 acute cerebral infarction patients (CI group) and 49 healthy people (NC group) by ELISA. Results 24 hours, 2 to 5 days and 28 days after occurrence of the acute cerebral infarction, the levels of serum MMP-- 2 in CI group were(46.29 ± 14.37) μg/L, (62.18±12.32) μg/L, and(35.72± 8. 91 )μg/L respectively; A significant increase in the levels of serum MMP-- 2 was found in CI group 2 to 5 days after occurrence of this disease compared to NC group (P 〈0.05). The levels of serum TIMP--2 in CI group, however, were significantly reduced 2--5 day after occurrence of this disease compared to NC group (P〈 0.05). Conclusions MMP--2 and TIMP--2 may contribute the pathologic process of cerebral infarction, and the levels of MMP--2 and TIMP--2 are correlated with the clinical course of this disease.
出处 《神经疾病与精神卫生》 2009年第4期313-315,共3页 Journal of Neuroscience and Mental Health
关键词 急性脑梗死 基质金属蛋白酶-2 基质金属蛋白酶组织抑制因子-2 Acute cerebral infarction Matrix metalloproteinase--2 Tissue metalloproteinase inhibitor-- 2
  • 相关文献

参考文献12

  • 1Galis ZS,Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly [J]. CircRes,2002,90(3):251-262.
  • 2Serena J, Blanco M, Castellanos M, et al. The prediction of malignant cerebral infarction by molecular brain barrier dis ruption markers[J]. Stroke,2005,36(9) : 1 921 - 1 926.
  • 3Neumann- ttaefelin T, Kastrup A, Crespigny A, et al. Serial MRI after transient focal cerebral ischemia in rats,dynamics of tissue injury, blood brain barrier damage, and edema formation [J].Stroke,2000,31(8) :1 968-1 973.
  • 4FatarM,StroickM,GriebeM,et al. Matrix metalloproteinases in cerebrovascular diseases[J]. Cerebrovasc Dis,2005, 20 (3):141.
  • 5Lee E, Grodzinsky A J, Libby P, et al. Human vascular smooth muscle cell-monocyte interactions? and metalloproteinase secretion in culture[J].Arterioscler Thromb Vasc Biol, 1995,15 (12) :2 284-2 289.
  • 6Rosenberg GA, Navratil M, Barone F, et al. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat[J]. Cereb Blood Flow Metab,1996,16(3):360- 366.
  • 7Romanic AM,White RF,Arleth AJ,et al. Matrix metallopro teinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size[J]. Stroke, 1998,29(5):1 020-1030.
  • 8Nakaji K,Ihara M,Takahashi C,et al. MMP-2 play a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents[J].Stroke, 2006,37 ( 11 ) : 2 816-2 823.
  • 9Heo J H, Lueero J, Abumiya T, et al. Matrix metalloproteinases increase very early during experimental foeat cerebral ischemia[J].J Cereb Blood Flow Metab, 1999,19(6) :624-633.
  • 10Horstmann S, Kalb P, Koziol J, Gardner H,et al. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies[J]. Stroke, 2003,34(9) :2 165-2 170.

二级参考文献13

  • 1Newman KM,Jean-Claude J,Li H,et al.Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall[J].J Vasc Surg,1994,20:814~820.
  • 2Kenagy RD,Vergel S,Mattsson E,et al.The role of plasminogen,plasminogen activators,and matrix metalloproteimases in primate arterial smooth muscle cell migration[J].Arterioscler Thromb Vasc Biol,1996,16(11):1373~1382.
  • 3Green J,Wang M,Liu YE,et al.Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4[J].J Biol Chem,1996,271(48):30375~30380.
  • 4Apte SS,Olsen BR,Murphy G.The gene structure of tissue inhibitor of metalloproteinases(TIMP)-3 and its inhibitory activities define the distinct TIMP gene family[J].J Biol Chem,1999,274(24):12313~12319.
  • 5Madea A,Sobel RA.Matrix metalloproteinases in the normal human centrai nervous system,microglial nodules,and multiple sclerosis lesions[J].J Neuropathol Exp Neurol,1996,55(3):300~309.
  • 6Rosenberg GA,Okada Y,Fitridge R,et al.Microvascular basal lamina antracerebral hamorrhage in the rat[J].Neurology,1997,48(40):921~926.
  • 7Romanic AM,White RF,Arleth AJ,et al.Matrix metalloproteinases expression increases after cerebral focal ischemia in rats.Inhibition of matrix metalloproteinase-9 reduces infarct size[J].Stroke,1998,29(8):1020~1030.
  • 8Rosenberg GA,Navratil m,Barone F,et al.Proteolytic cascade enzymes increase in focal cerebral ischemia in rat[J].J Cereb Blood Flow Metab,1996,16(3):360~366.
  • 9Clark AW,Krekoski CA,Bou SS,et al.Increased gelatinase A(MMP-2) and gelatinase B(MMP-9) activities in human brain after focal ischemia[J].Neurosci Lett,1997,238(1-2):53~56.
  • 10Heo JH,Lucero J,Abumiya T,et al.Matrix metalloproteinases increase very early during experimental focal cerebral ischemia[J].J Cereb Blood Flow Metab,1999,19(6):624~633.

共引文献4

同被引文献21

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部